✦ LIBER ✦

Prophylaxis in ovarian cancer

✍ Scribed by Hugh R. K. Barber

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 578 KB
Volume: 71
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.2820710419

No coin nor oath required. For personal study only.

✦ Synopsis

It has been shown that women who have taken the oral contraceptive pill for 4 or 5 years decreases the incidence of ovarian cancer by approximately 40%. It is estimated that the oral contraceptive pill can prevent approximately 1500 ovarian cancers each year.

The postmenopausal palpable ovary syndrome is simply the palpation of what is interpreted as a normalsized ovary in the premenopausal woman represents an ovarian tumor in the postmenopausal woman. It addresses the size and consistency and has nothing to do with the small cysts reported by the sonographer.

A patient who has two first-degree blood relatives or a mother, sister, or daughter who has developed ovarian cancer premenopausally is at high risk to develop ovarian cancer.

Because ovarian cancer is the leading cause of death from gynecologic cancer, it is important to explore all options for prophylaxis in the prevention of ovarian cancer. Cancer 1993; 71:1529-33.

📜 SIMILAR VOLUMES

Post-sepsis prophylaxis in cancer patien

Post-sepsis prophylaxis in cancer patients

✍ Walter T. Hughes; Gayle Patterson 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB

Ovarian cancer

✍ Jacques Dauplat 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 1 views

Centrosome abnormalities in ovarian canc

Centrosome abnormalities in ovarian cancer

✍ Lih-Ching Hsu; Malathy Kapali; Julie A. DeLoia; Holly H. Gallion 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 254 KB

## Abstract Centrosome abnormalities have been found in various cancer types and are thought to be involved in early development of cancer and/or progression. The contribution of centrosome abnormalities to ovarian tumorigenesis has not been previously evaluated. We sought to determine whether cent

New players in ovarian cancer

✍ Alessandro Bovicelli; Giuseppina D'Andrilli; Antonio Giordano 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

## Abstract Ovarian cancer is the leading cause of gynecologic cancer mortality worldwide. The aim of this review is to highlight the most recent studies regarding ovarian cancer pathogenesis and the new therapeutic approaches against this insidious disease. We focus on the relevance of some cell c

Hereditary ovarian cancer in Poland

✍ Janusz Menkiszak; Jacek Gronwald; Bohdan Górski; Anna Jakubowska; Tomasz Huzarsk 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 81 KB

There is increasing evidence that hereditary factors play a greater role in ovarian cancer than in any of the other common cancers of adulthood. This is attributable, to a large extent, to a high frequency of mutations in the BRCA1 or BRCA2 genes. In Poland, 3 common founder mutations in BRCA1 accou

Multidrug resistance in ovarian cancer

✍ Antonio Fojo; Thomas C. Hamilton; Robert C. Young; Robert F. Ozols 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 687 KB

The development of acquired resistance has limited the effectiveness of chemotherapy in the treatment of ovarian cancer. Experimental model systems were developed to study the mechanisms associated with primary resistance to chemotherapeutic agents and broad cross-resistance (multidrug resistance) w